Please enable JavaScript to continue using this application.

Compare $CRVS vs $GLUE | Chartloom

Compare

$CRVS vs $GLUE

Corvus Pharmaceuticals Inc · Monte Rosa Therapeutics Inc

CRVS

Corvus Pharmaceuticals Inc

GLUE

Monte Rosa Therapeutics Inc

Compare $CRVS vs $GLUE

Comparing Corvus Pharmaceuticals Inc and Monte Rosa Therapeutics Inc

CRVSCorvus Pharmaceuticals Inc

GLUEMonte Rosa Therapeutics Inc

CRVSCorvus Pharmaceuticals Inc

Market cap

$885M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

43.7%

52W performance

50.3%

FCF yield

-5.1%

GLUEMonte Rosa Therapeutics Inc

Market cap

$870M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

21.85x

Rev growth (TTM)

-83.9%

YTD performance

-32.7%

52W performance

33.6%

FCF yield

-3.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CRVS

GLUE

Detailed metrics comparison

CRVS

Corvus Pharmaceuticals Inc

GLUE

Monte Rosa Therapeutics Inc

Market Cap

CRVS$885M

GLUE$870M

Enterprise Value

CRVS$866M

GLUE$780M

Price

CRVS$10.52

GLUE$10.30

P/E Ratio

CRVSN/A

GLUEN/A

P/S Ratio

CRVS0.00x

GLUE30.29x

EV/Sales

CRVS0.00x

GLUE27.15x

EV/EBITDA

CRVS0.00x

GLUE47.84x

P/B Ratio

CRVS4.07x

GLUE1.84x

P/FCF Ratio

CRVSN/A

GLUEN/A

EV/FCF

CRVS-19.14x

GLUE-24.32x

PEG Ratio

CRVSN/A

GLUEN/A

Forward P/E (NTM)

CRVSN/A

GLUEN/A

Forward P/S (NTM)

CRVSN/A

GLUE21.85x

Revenue (TTM)

CRVS$0

GLUE$29M

Revenue Growth (YoY)

CRVSN/A

GLUE-83.9%

Forward Rev Growth

CRVS1220.6%

GLUE-58.1%

Gross Margin (TTM)

CRVS0.0%

GLUE0.0%

Operating Margin (TTM)

CRVS0.0%

GLUE0.0%

EBITDA Margin (TTM)

CRVS0.0%

GLUE-604.8%

Net Margin (TTM)

CRVS0.0%

GLUE-560.9%

FCF Margin (TTM)

CRVSN/A

GLUE-111.7%

Net Income (TTM)

CRVS$-54M

GLUE$-161M

FCF (TTM)

CRVS$-45M

GLUE$-32M

EPS (TTM)

CRVS-$0.59

GLUE-$1.59

ROE (TTM)

CRVS-3615.0%

GLUE-4331.0%

ROA (TTM)

CRVS-3362.0%

GLUE-2759.0%

ROIC (TTM)

CRVS-3615.0%

GLUE-4331.0%

Cash

CRVS$19M

GLUE$90M

Debt

CRVS$0

GLUE$0

Net Cash/Debt

CRVS$19M

GLUE$90M

Current Ratio (TTM)

CRVS16.16x

GLUE10.58x

Quick Ratio (TTM)

CRVS15.92x

GLUE10.49x

Debt/Equity (TTM)

CRVS0.00x

GLUE0.00x

Debt/Assets (TTM)

CRVS0.0%

GLUE0.0%

Interest Coverage (TTM)

CRVSN/A

GLUEN/A

Net Debt/EBITDA (TTM)

CRVS0.00x

GLUE0.00x

Beta

CRVS1.59

GLUE1.34

52W Performance

CRVS50.3%

GLUE33.6%

YTD Performance

CRVS43.7%

GLUE-32.7%

% from 52W High

CRVS-61.0%

GLUE-60.0%

% from 52W Low

CRVS64.6%

GLUE34.7%

Asset Turnover (TTM)

CRVS0.00x

GLUE0.05x

FCF Yield (TTM)

CRVS-5.1%

GLUE-3.7%

Earnings Yield (TTM)

CRVS-6.1%

GLUE-18.5%

Dividend Yield (TTM)

CRVSN/A

GLUEN/A

Rule of 40

CRVS0.0

GLUE-195.5

EV/GP/RG

CRVSN/A

GLUEN/A

Ticker research

View CRVS research View GLUE research

Metric	CRVS Corvus Pharmaceuticals Inc	GLUE Monte Rosa Therapeutics Inc
Market & Valuation
Market Cap	$885M	$870M
Enterprise Value	$866M	$780M
Price	$10.52	$10.30
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	30.29x
EV/Sales	0.00x	27.15x
EV/EBITDA	0.00x	47.84x
P/B Ratio	4.07x	1.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.14x	-24.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	21.85x
Revenue & Growth
Revenue (TTM)	$0	$29M
Revenue Growth (YoY)	N/A	-83.9%
Forward Rev Growth	1220.6%	-58.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-604.8%
Net Margin (TTM)	0.0%	-560.9%
FCF Margin (TTM)	N/A	-111.7%
Net Income (TTM)	$-54M	$-161M
FCF (TTM)	$-45M	$-32M
EPS (TTM)	-$0.59	-$1.59
ROE (TTM)	-3615.0%	-4331.0%
ROA (TTM)	-3362.0%	-2759.0%
ROIC (TTM)	-3615.0%	-4331.0%
Financial Health
Cash	$19M	$90M
Debt	$0	$0
Net Cash/Debt	$19M	$90M
Current Ratio (TTM)	16.16x	10.58x
Quick Ratio (TTM)	15.92x	10.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	1.34
52W Performance	50.3%	33.6%
YTD Performance	43.7%	-32.7%
% from 52W High	-61.0%	-60.0%
% from 52W Low	64.6%	34.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-5.1%	-3.7%
Earnings Yield (TTM)	-6.1%	-18.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-195.5
EV/GP/RG	N/A	N/A
Ticker research	View CRVS research	View GLUE research

Valuation

P/S Ratio

CRVS

0.00x

GLUE

30.29x

EV/FCF

GLUE

-24.32x

CRVS

-19.14x

Growth & revenue

Revenue Growth TTM

GLUE

-83.9%

Forward Revenue Growth

CRVS

1220.6%

GLUE

-58.1%

Profitability & performance

Gross Margin

CRVS

0.0%

GLUE

0.0%

ROE

CRVS

-3615.0%

GLUE

-4331.0%

FCF Yield %

GLUE

-3.7%

CRVS

-5.1%

52-Week Performance

CRVS

50.3%

GLUE

33.6%

Detailed metrics comparison

CRVS

Corvus Pharmaceuticals Inc

GLUE

Monte Rosa Therapeutics Inc

Market Cap

CRVS$885M

GLUE$870M

Enterprise Value

CRVS$866M

GLUE$780M

Price

CRVS$10.52

GLUE$10.30

P/E Ratio

CRVSN/A

GLUEN/A

P/S Ratio

CRVS0.00x

GLUE30.29x

EV/Sales

CRVS0.00x

GLUE27.15x

EV/EBITDA

CRVS0.00x

GLUE47.84x

P/B Ratio

CRVS4.07x

GLUE1.84x

P/FCF Ratio

CRVSN/A

GLUEN/A

EV/FCF

CRVS-19.14x

GLUE-24.32x

PEG Ratio

CRVSN/A

GLUEN/A

Forward P/E (NTM)

CRVSN/A

GLUEN/A

Forward P/S (NTM)

CRVSN/A

GLUE21.85x

Revenue (TTM)

CRVS$0

GLUE$29M

Revenue Growth (YoY)

CRVSN/A

GLUE-83.9%

Forward Rev Growth

CRVS1220.6%

GLUE-58.1%

Gross Margin (TTM)

CRVS0.0%

GLUE0.0%

Operating Margin (TTM)

CRVS0.0%

GLUE0.0%

EBITDA Margin (TTM)

CRVS0.0%

GLUE-604.8%

Net Margin (TTM)

CRVS0.0%

GLUE-560.9%

FCF Margin (TTM)

CRVSN/A

GLUE-111.7%

Net Income (TTM)

CRVS$-54M

GLUE$-161M

FCF (TTM)

CRVS$-45M

GLUE$-32M

EPS (TTM)

CRVS-$0.59

GLUE-$1.59

ROE (TTM)

CRVS-3615.0%

GLUE-4331.0%

ROA (TTM)

CRVS-3362.0%

GLUE-2759.0%

ROIC (TTM)

CRVS-3615.0%

GLUE-4331.0%

Cash

CRVS$19M

GLUE$90M

Debt

CRVS$0

GLUE$0

Net Cash/Debt

CRVS$19M

GLUE$90M

Current Ratio (TTM)

CRVS16.16x

GLUE10.58x

Quick Ratio (TTM)

CRVS15.92x

GLUE10.49x

Debt/Equity (TTM)

CRVS0.00x

GLUE0.00x

Debt/Assets (TTM)

CRVS0.0%

GLUE0.0%

Interest Coverage (TTM)

CRVSN/A

GLUEN/A

Net Debt/EBITDA (TTM)

CRVS0.00x

GLUE0.00x

Beta

CRVS1.59

GLUE1.34

52W Performance

CRVS50.3%

GLUE33.6%

YTD Performance

CRVS43.7%

GLUE-32.7%

% from 52W High

CRVS-61.0%

GLUE-60.0%

% from 52W Low

CRVS64.6%

GLUE34.7%

Asset Turnover (TTM)

CRVS0.00x

GLUE0.05x

FCF Yield (TTM)

CRVS-5.1%

GLUE-3.7%

Earnings Yield (TTM)

CRVS-6.1%

GLUE-18.5%

Dividend Yield (TTM)

CRVSN/A

GLUEN/A

Rule of 40

CRVS0.0

GLUE-195.5

EV/GP/RG

CRVSN/A

GLUEN/A

Ticker research

View CRVS research View GLUE research

Metric	CRVS Corvus Pharmaceuticals Inc	GLUE Monte Rosa Therapeutics Inc
Market & Valuation
Market Cap	$885M	$870M
Enterprise Value	$866M	$780M
Price	$10.52	$10.30
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	30.29x
EV/Sales	0.00x	27.15x
EV/EBITDA	0.00x	47.84x
P/B Ratio	4.07x	1.84x
P/FCF Ratio	N/A	N/A
EV/FCF	-19.14x	-24.32x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	21.85x
Revenue & Growth
Revenue (TTM)	$0	$29M
Revenue Growth (YoY)	N/A	-83.9%
Forward Rev Growth	1220.6%	-58.1%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-604.8%
Net Margin (TTM)	0.0%	-560.9%
FCF Margin (TTM)	N/A	-111.7%
Net Income (TTM)	$-54M	$-161M
FCF (TTM)	$-45M	$-32M
EPS (TTM)	-$0.59	-$1.59
ROE (TTM)	-3615.0%	-4331.0%
ROA (TTM)	-3362.0%	-2759.0%
ROIC (TTM)	-3615.0%	-4331.0%
Financial Health
Cash	$19M	$90M
Debt	$0	$0
Net Cash/Debt	$19M	$90M
Current Ratio (TTM)	16.16x	10.58x
Quick Ratio (TTM)	15.92x	10.49x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.59	1.34
52W Performance	50.3%	33.6%
YTD Performance	43.7%	-32.7%
% from 52W High	-61.0%	-60.0%
% from 52W Low	64.6%	34.7%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.05x
FCF Yield (TTM)	-5.1%	-3.7%
Earnings Yield (TTM)	-6.1%	-18.5%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-195.5
EV/GP/RG	N/A	N/A
Ticker research	View CRVS research	View GLUE research